TNFα in synaptic function: Switching gears

Trends in Neurosciences

Volumn 35, Issue 10, 2012, Pages 638-647

  Santello, Mirko ^a   Volterra, Andrea ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Cytokines; Glia; Gliotransmission; Inflammation; Synaptic transmission; TNF

Indexed keywords

AMPA RECEPTOR; GLUTAMIC ACID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ASTROCYTE; CELL MIGRATION; HUMAN; NERVE CELL PLASTICITY; NERVOUS SYSTEM FUNCTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYNAPTIC FUNCTION; SYNAPTIC TRANSMISSION;

ANIMALS; ASTROCYTES; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; GLUTAMIC ACID; HUMANS; MODELS, BIOLOGICAL; NEURONAL PLASTICITY; RECEPTORS, AMPA; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866751526     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2012.06.001     Document Type: Review

References (105)

1. Rivest S. Regulation of innate immune responses in the brain. Nat. Rev. Immunol. 2009, 9:429-439.
2. Boulanger L.M. Immune proteins in brain development and synaptic plasticity. Neuron 2009, 64:93-109.
3. Bailey S.L., et al. Innate and adaptive immune responses of the central nervous system. Crit. Rev. Immunol. 2006, 26:149-188.
4. Ransohoff R.M., Cardona A.E. The myeloid cells of the central nervous system parenchyma. Nature 2010, 468:253-262.
5. Carpentier P.A., Palmer T.D. Immune influence on adult neural stem cell regulation and function. Neuron 2009, 64:79-92.
6. Santello M., et al. TNFalpha controls glutamatergic gliotransmission in the hippocampal dentate gyrus. Neuron 2011, 69:988-1001.
7. Stellwagen D., Malenka R.C. Synaptic scaling mediated by glial TNF-alpha. Nature 2006, 440:1054-1059.
8. Bezzi P., et al. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat. Neurosci. 2001, 4:702-710.
9. Lue L.F., et al. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 2001, 35:72-79.
10. Gregersen R., et al. Microglia and macrophages are the major source of tumor necrosis factor in permanent middle cerebral artery occlusion in mice. J. Cereb. Blood Flow Metab. 2000, 20:53-65.
11. Boka G., et al. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinsons disease. Neurosci. Lett. 1994, 172:151-154.
12. Vezzani A., et al. Functional role of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. Epilepsia 2002, 43:30-35.
13. Sriram K., O'Callaghan J.P. Divergent roles for tumor necrosis factor-alpha in the brain. J. Neuroimmune Pharmacol. 2007, 2:140-153.
14. Frankola K.A., et al. Targeting TNF-alpha to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. CNS Neurol. Disord. Drug Targets 2011, 10:391-403.
15. Montgomery S.L., Bowers W.J. Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system. J. Neuroimmune Pharmacol. 2012, 7:42-59.
16. McCoy M.K., Tansey M.G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflamm. 2008, 5:45.
17. Brambilla R., et al. Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain 2011, 134:2736-2754.
18. Zhang D.W., et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009, 325:332-336.
19. Li R., et al. Tumor necrosis factor death receptor signaling cascade is required for amyloid-beta protein-induced neuron death. J. Neurosci. 2004, 24:1760-1771.
20. He P., et al. Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J. Cell Biol. 2007, 178:829-841.
21. Shen Y., et al. Distinct destructive signal pathways of neuronal death in Alzheimer's disease. Trends Mol. Med. 2006, 12:574-579.
22. Song J.H., et al. Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. J. Neurosci. 2006, 26:3299-3308.
23. Kitsberg D., et al. Knock-out of the neural death effector domain protein PEA-15 demonstrates that its expression protects astrocytes from TNFalpha-induced apoptosis. J. Neurosci. 1999, 19:8244-8251.
24. Rothe M., et al. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995, 83:1243-1252.
25. Sud R., et al. Uncovering molecular elements of brain-body communication during development and treatment of neuropathic pain. Brain Behav. Immun. 2007, 21:112-124.
26. Ren W.J., et al. Peripheral nerve injury leads to working memory deficits and dysfunction of the hippocampus by upregulation of TNF-alpha in rodents. Neuropsychopharmacology 2011, 36:979-992.
27. McCoy M.K., et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. 2006, 26:9365-9375.
28. McAlpine F.E., et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol. Dis. 2009, 34:163-177.
29. Cheng X., et al. Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients. J. Alzheimers Dis. 2010, 19:621-630.
30. Akassoglou K., et al. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am. J. Pathol. 1998, 153:801-813.
31. Balosso S., et al. Tumor necrosis factor-alpha inhibits seizures in mice via p75 receptors. Ann. Neurol. 2005, 57:804-812.
32. Balosso S., et al. Molecular and functional interactions between tumor necrosis factor-alpha receptors and the glutamatergic system in the mouse hippocampus: implications for seizure susceptibility. Neuroscience 2009, 161:293-300.
33. Baxter A.G. The origin and application of experimental autoimmune encephalomyelitis. Nat. Rev. Immunol. 2007, 7:904-912.
34. Eugster H.P., et al. Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. Eur. J. Immunol. 1999, 29:626-632.
35. Liu J., et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat. Med. 1998, 4:78-83.
36. Suvannavejh G.C., et al. Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis. Cell. Immunol. 2000, 205:24-33.
37. Arnett H.A., et al. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. 2001, 4:1116-1122.
38. Fontaine V., et al. Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J. Neurosci. 2002, 22:RC216.
39. Nadeau S., et al. Functional recovery after peripheral nerve injury is dependent on the pro-inflammatory cytokines IL-1 beta and TNF: implications for neuropathic pain. J. Neurosci. 2011, 31:12533-12542.
40. Zhang H.J., et al. Ap38 mitogen-activated protein kinase-dependent mechanism of disinhibition in spinal synaptic transmission induced by tumor necrosis factor-alpha. J. Neurosci. 2010, 30:12844-12855.
41. Yang L., et al. Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J. Neurosci. 2002, 22:3025-3032.
42. Bernardino L., et al. Modulator effects of interleukin-1beta and tumor necrosis factor-alpha on AMPA-induced excitotoxicity in mouse organotypic hippocampal slice cultures. J. Neurosci. 2005, 25:6734-6744.
43. Galasso J.M., et al. Inhibition of TNF-alpha can attenuate or exacerbate excitotoxic injury in neonatal rat brain. Neuroreport 2000, 11:231-235.
44. Bruce A.J., et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat. Med. 1996, 2:788-794.
45. Lambertsen K.L., et al. Microglia protect neurons against ischemia by synthesis of tumor necrosis factor. J. Neurosci. 2009, 29:1319-1330.
46. Vitkovic L., et al. 'Inflammatory' cytokines: neuromodulators in normal brain?. J. Neurochem. 2000, 74:457-471.
47. Cearley C., et al. Time of day differences in IL1beta and TNFalpha mRNA levels in specific regions of the rat brain. Neurosci. Lett. 2003, 352:61-63.
48. Bredow S., et al. Diurnal variations of tumor necrosis factor alpha mRNA and alpha-tubulin mRNA in rat brain. Neuroimmunomodulation 1997, 4:84-90.
49. Krueger J.M. The role of cytokines in sleep regulation. Curr. Pharm. Des. 2008, 14:3408-3416.
50. Banks W.A., et al. Regional transport of TNF-alpha across the blood-brain barrier in young ICR and young and aged SAMP8 mice. Neurobiol. Aging 2001, 22:671-676.
51. Pollmacher T., et al. Low levels of circulating inflammatory cytokines: do they affect human brain functions?. Brain Behav. Immun. 2002, 16:525-532.
52. Imeri L., Opp M.R. How (and why) the immune system makes us sleep. Nat. Rev. Neurosci. 2009, 10:199-210.
53. Krueger J.M., et al. Sleep. A physiologic role for IL-1 beta and TNF-alpha. Ann. N. Y. Acad. Sci. 1998, 856:148-159.
54. Baune B.T., et al. Cognitive dysfunction in mice deficient for TNF-, its receptors. Am. J. Med. Genet. A 2008, 147B:1056-1064.
55. Baune B.T., et al. Association between genetic variants of IL-1beta, IL-6 and TNF-alpha cytokines and cognitive performance in the elderly general population of the MEMO-study. Psychoneuroendocrinology 2008, 33:68-76.
56. Beste C., et al. Variations in the TNF-α gene (TNF-α -308G→A) affect attention and action selection mechanisms in a dissociated fashion. J. Neurophysiol. 2010, 104:2523-2531.
57. Plata-Salaman C.R. Cytokines and feeding. Int. J. Obes. Relat. Metab. Disord. 2001, 25(Suppl. 5):S48-S52.
58. Besedovsky H.O., del Rey A. Central and peripheral cytokines mediate immune-brain connectivity. Neurochem. Res. 2011, 36:1-6.
59. Churchill L., et al. Tumor necrosis factor alpha: activity dependent expression and promotion of cortical column sleep in rats. Neuroscience 2008, 156:71-80.
60. Pickering M., et al. Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp. Physiol. 2005, 90:663-670.
61. Kandel E.R. The molecular biology of memory storage: a dialogue between genes and synapses. Science 2001, 294:1030-1038.
62. Turrigiano G.G. The self-tuning neuron: synaptic scaling of excitatory synapses. Cell 2008, 135:422-435.
63. Beattie E.C., et al. Control of synaptic strength by glial TNFalpha. Science 2002, 295:2282-2285.
64. Stellwagen D., et al. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J. Neurosci. 2005, 25:3219-3228.
65. Stuck E.D., et al. Tumor necrosis factor alpha mediates GABA(A) receptor trafficking to the plasma membrane of spinal cord neurons in vivo. Neural Plast. 2012, 10.1155/2012/261345.
66. Beattie M.S., et al. AMPA-receptor trafficking and injury-induced cell death. Eur. J. Neurosci. 2010, 32:290-297.
67. Leonoudakis D., et al. Rapid tumor necrosis factor alpha-induced exocytosis of glutamate receptor 2-lacking AMPA receptors to extrasynaptic plasma membrane potentiates excitotoxicity. J. Neurosci. 2008, 28:2119-2130.
68. Ferguson A.R., et al. Cell death after spinal cord injury is exacerbated by rapid TNF alpha-induced trafficking of GluR2-lacking AMPARs to the plasma membrane. J. Neurosci. 2008, 28:11391-11400.
69. He P., et al. Genetic deletion of TNF receptor suppresses excitatory synaptic transmission via reducing AMPA receptor synaptic localization in cortical neurons. FASEB J. 2012, 26:334-345.
70. Centonze D., et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J. Neurosci. 2009, 29:3442-3452.
71. Kaneko M., et al. Tumor necrosis factor-alpha mediates one component of competitive, experience-dependent plasticity in developing visual cortex. Neuron 2008, 58:673-680.
72. Kerchner G.A., Nicoll R.A. Silent synapses and the emergence of a postsynaptic mechanism for LTP. Nat. Rev. Neurosci. 2008, 9:813-825.
73. Steinmetz C.C., Turrigiano G.G. Tumor necrosis factor-alpha signaling maintains the ability of cortical synapses to express synaptic scaling. J. Neurosci. 2010, 30:14685-14690.
74. Shatz C.J. Impulse activity and the patterning of connections during CNS development. Neuron 1990, 5:745-756.
75. Aizenman C.D., Pratt K.G. There's more than one way to scale a synapse. Neuron 2008, 58:651-653.
76. Albensi B.C., Mattson M.P. Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse 2000, 35:151-159.
77. Tancredi V., et al. Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci. Lett. 1992, 146:176-178.
78. Cunningham A.J., et al. Interleukin-1 beta (IL-1 beta) and tumour necrosis factor (TNF) inhibit long-term potentiation in the rat dentate gyrus in vitro. Neurosci. Lett. 1996, 203:17-20.
79. Cumiskey D., et al. Evidence for a role for the group I metabotropic glutamate receptor in the inhibitory effect of tumor necrosis factor-alpha on long-term potentiation. Brain Res. 2007, 1136:13-19.
80. Butler M.P., et al. Dissection of tumor-necrosis factor-alpha inhibition of long-term potentiation (LTP) reveals a p38 mitogen-activated protein kinase-dependent mechanism which maps to early-but not late-phase LTP. Neuroscience 2004, 124:319-326.
81. Costello D.A., et al. Long term potentiation is impaired in membrane glycoprotein CD200-deficient mice: a role for Toll-like receptor activation. J. Biol. Chem. 2011, 286:34722-34732.
82. Wang Q., et al. Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur. J. Neurosci. 2005, 22:2827-2832.
83. Wang Q., et al. Developmental dependence, the role of the kinases p38 MAPK and PKC, and the involvement of tumor necrosis factor-R1 in the induction of mGlu-5 LTD in the dentate gyrus. Neuroscience 2007, 144:110-118.
84. Halassa M.M., Haydon P.G. Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annu. Rev. Physiol. 2010, 72:335-355.
85. Perea G., et al. Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci. 2009, 32:421-431.
86. Bezzi P., et al. Astrocytes contain a vesicular compartment that is competent for regulated exocytosis of glutamate. Nat. Neurosci. 2004, 7:613-620.
87. Domercq M., et al. P2Y1 receptor-evoked glutamate exocytosis from astrocytes: control by tumor necrosis factor-alpha and prostaglandins. J. Biol. Chem. 2006, 281:30684-30696.
88. Jourdain P., et al. Glutamate exocytosis from astrocytes controls synaptic strength. Nat. Neurosci. 2007, 10:331-339.
89. Di Castro M.A., et al. Local Ca2+ detection and modulation of synaptic release by astrocytes. Nat. Neurosci. 2011, 14:1276-1287.
90. Miyoshi J., Takai Y. Dual role of DENN/MADD (Rab3GEP) in neurotransmission and neuroprotection. Trends Mol. Med. 2004, 10:476-480.
91. Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat. Rev. Mol. Cell Biol. 2009, 10:513-525.
92. Bezzi P., et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 1998, 391:281-285.
93. Grassi F., et al. TNF-alpha increases the frequency of spontaneous miniature synaptic currents in cultured rat hippocampal-neurons. Brain Res. 1994, 659:226-230.
94. Jia D., et al. TNF-alpha involves in altered prefrontal synaptic transmission in mice with persistent inflammatory pain. Neurosci. Lett. 2007, 415:1-5.
95. Zhang L., et al. TNF-alpha contributes to spinal cord synaptic plasticity and inflammatory pain: distinct role of TNF receptor subtypes 1 and 2. Pain 2011, 152:419-427.
96. Kawasaki Y., et al. Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1 beta, interleukin-6, and tumor necrosis factor-beta in regulating synaptic and neuronal activity in the superficial spinal cord. J. Neurosci. 2008, 28:5189-5194.
97. Youn D.H., et al. Exogenous tumor necrosis factor-alpha rapidly alters synaptic and sensory transmission in the adult rat spinal cord dorsal horn. J. Neurosci. Res. 2008, 86:2867-2875.
98. Xu Z.Z., et al. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat. Med. 2010, 16:592-597.
99. Spicarova D., et al. Modulation of spinal cord synaptic activity by tumor necrosis factor alpha in a model of peripheral neuropathy. J. Neuroinflamm. 2011, 8:177.
100. Han P.C., Whelan P.J. Tumor necrosis factor alpha enhances glutamatergic transmission onto spinal motoneurons. J. Neurotrauma 2010, 27:287-292.
101. Floyd R.A., Krueger J.M. Diurnal variation of TNF alpha in the rat brain. Neuroreport 1997, 8:915-918.
102. Tobinick E. Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence. CNS Drugs 2009, 23:713-725.
103. Renauld A.E., et al. alpha(2)-adrenergic receptor inhibition of cAMP accumulation is transformed to facilitation by tumor necrosis factor-alpha. Brain Res. 2004, 1004:212-216.
104. Limatola C., et al. SDF-1alpha-mediated modulation of synaptic transmission in rat cerebellum. Eur. J. Neurosci. 2000, 12:2497-2504.
105. Gregory A.P., et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 2012, 488:508-511.